{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"BridgeBio Oncology Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"BBOT"},"Address":{"label":"Address","value":"C/O CORMORANT ASSET MANAGEMENT, LP,200 CLARENDON STREET,52ND FLOOR, BOSTON, Massachusetts, 02116, United States"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, visit bbotx.com."},"CompanyUrl":{"label":"Company Url","value":null}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}